Combotope Therapeutics Enters into Collaboration with Boehringer Ingelheim to Advance First-in-Class Tumor-Selective Antibody Therapies for Cancer

Contributed by: PR Newswire

Tags

COMBOTOPE-collab-BI

More Like This

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

PR Newswire associated0

Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family